Evaluation of Growth Differentiation Factor-15 levels in Rheumatoid Arthritis Iraqi Patients with and without diabetes
Keywords:
Growth Differentiation Factor-15, Rheumatoid Arthritis, Diabetes Mellitus Type 2, Inflammation.Abstract
Background: The underlying cause due to rheumatoid arthritis (RA) depends heavily based on macrophages. Autocrine growth differentiation factor -15 (GDF-15) regulates the activation of macrophages. Objective: The purpose of this research was to look at serum GDF-15 concentrations as a possible marker of RA disease activity. Methods: This research enrolled 50 patients with RA as well as 50 healthy controls with identical demographics. The patient group was further subdivided equally based on the prevalence of diabetes disease. The concentrations the GDF-15 was measured using an ELISA, as well CRP; in addition, ESR levels were determined. Other parameters (lipid profile and glucose) were measured using colourimetric methods. Results: In contrast to the control group, the measurement of GDF-15 in the serum of RA people who are afflicted and without diabetes was significantly higher (P< 0.05). A negative relationship between GDF-15 using ESR (r=- 0.491; P<0.05), CRP) r=-0.465; P<0.05), in addition to TG (r=-0.428; P<0.05) was found. The receiver operating characteristic curve reveals that this marker has good sensitivity and specificity in RA patients with diabetes. Conclusion: An increase in levels of GDF-15 might be stabilizing and counteracting dysregulated inflammatory processes via a compensatory mechanism.
Downloads
References
van Delft MA, Huizinga TW. An overview of autoantibodies in
rheumatoid arthritis. Journal of autoimmunity. 2020;l10:102392.
Hassoon HJ, Jasim WE, Abbas AAH. The Evaluation of Some
Biomarkers According to Rheumatoid Factor in Early Diagnosis of
Rheumatoid Arthritis from Iraqi Patients. Iraqi Journal of Science.
:2196-203.
Lin Y-J, Anzaghe M, Schulke S. Update on the pathomechanism,
diagnosis, and treatment options for rheumatoid arthritis. Cells.
;9(4):880.
Al-Garawi Z, Tahir N, Tabatabai Z, Salman A, editors. The mechanism
of leptin and IGF-1 in the diabetic rheumatoid arthritis Iraqi
patients. Journal of Physics: Conference Series; 2021: IOP
Publishing.
Enad At, Alqadhi Bn. Effect Of Menopause On Different Cytokines
Levels And Proportion Of T-Regs In Rheumatoid Arthritis (Ra) Iraqi
Women.
RA H. irt! ie-it.
Enad AT, Alfahdawi AJ, Bedair NH. Correlation Between Menopause
and Inflammatory Markers with Das28 Among Iraqi Patients with
Rheumatoid Arthritis. AL-MANSOUR JOURNAL. 2022(37).
Hamid ZA. The Impact of Hepatitis B Virus and Epstein-Barr Virus in
Pathogenesis of Rheumatoid Arthritis. Biomedical and
Pharmacology Journal. 2017;10(3):1495-501.
Albabawaty NS, Majid AY, Alosami MH, Mahmood HG. Role of high
sensitivity C-Reactive protein and some of heavy metals in patients
with rheumatoid arthritis. Ann Trop Med Public Health. 2020;23:16.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid
arthritis: a review. Jama. 2018;320(13):1360-72.
Scott D. Biologies based therapy for the treatment of rheumatoid
arthritis. Clinical Pharmacology & Therapeutics. 2012;91(1):30-43.
Wischhusen J, Melero I, Fridman WH. Growth/differentiation factor-15
(GDF-15): from biomarker to novel targetable immune checkpoint.
Frontiers in Immunology. 2020;11:951.
Chang JY, Hong HJ, Kang SG, Kim JT, Zhang BY, Shong M. The role of
growth differentiation factor 15 in energy metabolism. Diabetes &
Metabolism Journal. 2020;44(3):363-71.
Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in
diabetes and cardiovascular disease. Cytokine & growth factor
reviews. 2021;57:11-8.
Berezin AE. Diabetes mellitus related biomarker: The predictive role of
growth-differentiation factor-15. Diabetes & Metabolic Syndrome:
Clinical Research & Reviews. 2016;10(l):S154-S7.
Ye D, Liu B, He Z, Huang L, Qian Y, Shao K, et al. Assessing the
associations of growth differentiation factor 15 with rheumatic
diseases using genetic data. Clinical Epidemiology. 2021:245-52.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO,
et al. 2010 rheumatoid arthritis classification criteria: an American
College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis & rheumatism. 2010;62(9):2569-81.
Esalatmanesh K, Fayyazi H, Esalatmanesh R, Khabbazi A. The
association between serum levels of growth differentiation factor 15
and rheumatoid arthritis activity. International Journal of Clinical
Practice. 2020;74(9):el3564.
Xu W-D, Su L-C, He C-S, Huang A-F. Plasma interleukin-38 in patients
with rheumatoid arthritis. International immunopharmacology.
;65:1-7.
Van Riel P, Renskers L. The Disease ActivityScore (DAS) and the Disease
Activity Score using 28 joint counts (DAS28) in the management of
rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(5 Suppl
:S40-S4.
Tanrikulu O, Sanyildiz MA, Batmaz 1, Yazmalar L, Polat N, Kaplan 1, et
al. Serum GDF-15 level in rheumatoid arthritis: relationship with
disease activity and subclinical atherosclerosis. Acta reumatologica
portuguesa. 2017(1).
He Y-W, He C-S. Association of growth and differentiation factor 15 in
rheumatoid arthritis. Journal of Inflammation Research. 2022:1173-
Nicolau J, Lequerre T, Bacquet H, Vittecoq O. Rheumatoid arthritis,
insulin resistance, and diabetes. Joint Bone Spine. 2017;84(4):411-6.
Salih RKM, Al-Gharawi AM, Al-Lehibi KI. The Correlation Between Hyperglycemia and Rheumatoid Factor in Type 2 Diabetic Patients in Al-Risafa Area, Baghdad. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2012;21(l):105-ll.
Pope JE, Choy EH, editors. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Seminars in arthritis and rheumatism; 2021: Elsevier.
Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, et al. Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologies in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. The pharmacogenomics journal. 2014;14(2):171-5.
Charles Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis & rheumatology. 2015;67(3):616-25.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
